Trial Profile
A Phase II Trial of Revlimid and Rituximab, for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Biomarker; Therapeutic Use
- 27 Mar 2023 Status changed from active, no longer recruiting to completed.
- 02 Sep 2021 Planned End Date changed from 1 Apr 2021 to 1 Dec 2024.
- 04 Jun 2020 Planned End Date changed from 1 Mar 2021 to 1 Apr 2021.